Hoth Therapeutics: Funding, Investors & Team (Sep 2026)
Hoth Therapeutics is a company that is currently in the clinical stage of development in the biopharmaceutical field. They are dedicated to creating innovative therapies for dermatological disorders. HOTH's research and development efforts have the potential to greatly enhance the lives of patients suffering from conditions such as atopic dermatitis, chronic wounds, psoriasis, asthma, and acne. Recently, Hoth has formed a partnership to further advance the development of potential vaccines for the prevention, interception, or treatment of the Coronavirus (COVID-19) using the VaxCelerate platform. This platform is a self-assembling vaccine technology exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
Hoth Therapeutics has raised $11.9M across 3 funding rounds on record, the most recent an undisclosed round of $2.0M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Hoth Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Hoth Therapeutics Funding Rounds
Hoth Therapeutics raised $7.0M in a Post-IPO Equity announced in Apr 2022.
1.4 years later, an undisclosed round of $2.9M was announced in Sep 2023.
2.6 years later, an undisclosed round of $2.0M was announced in Apr 2026.
Hoth Therapeutics Founders and Leadership Team
Contact details for the Hoth Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Hoth Therapeutics Funding Compared to Other Biotechnology Startups
Hoth Therapeutics' latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Hoth Therapeutics in Biotechnology and New York
Companies Similar to Hoth Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Hoth Therapeutics Funding FAQs
What does Hoth Therapeutics do?
Hoth Therapeutics is a company that is currently in the clinical stage of development in the biopharmaceutical field. They are dedicated to creating innovative therapies for dermatological disorders. HOTH's research and development efforts have the potential to greatly enhance the lives of patients suffering from conditions such as atopic dermatitis, chronic wounds, psoriasis, asthma, and acne. Recently, Hoth has formed a partnership to further advance the development of potential vaccines for the prevention, interception, or treatment of the Coronavirus (COVID-19) using the VaxCelerate platform. This platform is a self-assembling vaccine technology exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
How much funding has Hoth Therapeutics raised?
Hoth Therapeutics has raised $11.9M across 3 rounds on record. The most recent is an undisclosed round of $2.0M announced in Apr 2026.
When did Hoth Therapeutics last raise funding?
Hoth Therapeutics' most recent funding round on record is an undisclosed round of $2.0M, announced in Apr 2026.
Who is the CEO of Hoth Therapeutics?
Robb Knie is listed as CEO at Hoth Therapeutics.
Where is Hoth Therapeutics headquartered?
Hoth Therapeutics is based in New York, United States.
How many employees does Hoth Therapeutics have?
Hoth Therapeutics is in the 1-10 employee band.
How does Hoth Therapeutics' funding compare to other Biotechnology startups?
Hoth Therapeutics' latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Hoth Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Hoth Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.